Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

他のバージョン（1件）を表示する

Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to...

書誌詳細
主要な著者:	Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A
フォーマット:	Journal article
言語:	English
出版事項:	2010

類似資料

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
著者:: Mele, T, 等
出版事項: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
著者:: Fox, S, 等
出版事項: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
著者:: Fox, S, 等
出版事項: (2011)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
著者:: Generali, D, 等
出版事項: (2009)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
著者:: Generali, D, 等
出版事項: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
著者:: Generali, D, 等
出版事項: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
著者:: Generali, D, 等
出版事項: (2007)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
著者:: Generali, D, 等
出版事項: (2008)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
著者:: Generali, D, 等
出版事項: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
著者:: Generali, D, 等
出版事項: (2006)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
著者:: Generali, D, 等
出版事項: (2006)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
著者:: Generali, D, 等
出版事項: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
著者:: Fox, S, 等
出版事項: (2006)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
著者:: Generali, D, 等
出版事項: (2011)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
著者:: Foroni, C, 等
出版事項: (2009)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
著者:: Allevi, G, 等
出版事項: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
著者:: Allevi, G, 等
出版事項: (2013)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
著者:: Andreis, D, 等
出版事項: (2016)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
著者:: Milani, M, 等
出版事項: (2009)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
著者:: A Ianza, 等
出版事項: (2020-06-01)

Tamoxifen for Breast Cancer
著者:: A Karn, 等
出版事項: (2010-03-01)

Nanoparticle Effect on Interaction of Epirubicin with DNA
著者:: Leyla Karadurmus, 等
出版事項: (2017-11-01)

WITHDRAWN: Tamoxifen for early breast cancer.
著者:: Clarke, M
出版事項: (2008)

Vitamin C-driven epirubicin loading into liposomes
著者:: Lipka D, 等
出版事項: (2013-09-01)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
著者:: Kerstin Wimmer, 等
出版事項: (2023-11-01)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
著者:: Andreas Venizelos, 等
出版事項: (2022-08-01)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
著者:: Yuntao Wang MS, 等
出版事項: (2021-03-01)

Screening of oral tamoxifen ocular toxicity in patients with breast cancer
著者:: Ahmed Tharwat, 等
出版事項: (2022-01-01)

Modern breast cancer therapy: from tamoxifen to T-cell engineering
著者:: Yu. A. Shevchenko, 等
出版事項: (2022-11-01)

Tamoxifen in breast conservation therapy.
著者:: Lee, K, 等
出版事項: (1995)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
著者:: Yuanyuan Shen, 等
出版事項: (2024-12-01)

Effect of Two Administration Methods of Endostar Combined with Epirubicin on Breast Cancer in Mice
著者:: WU Jiao, 等
出版事項: (2018-07-01)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
著者:: Liu L, 等
出版事項: (2017-06-01)

Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
著者:: Erdim Refik, 等
出版事項: (2009-09-01)

Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.
著者:: Giatromanolaki, A, 等
出版事項: (2002)

Early and late tamoxifen resistance in breast cancer
著者:: Abu Rabi Z., 等
出版事項: (2010-01-01)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
著者:: Seo Yun Moon, 等
出版事項: (2021-08-01)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
著者:: Lundgren Steinar, 等
出版事項: (2010-06-01)

Sox2 promotes tamoxifen resistance in breast cancer cells
著者:: Marco Piva, 等
出版事項: (2013-10-01)

Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer
著者:: Hany N. Azzam, 等
出版事項: (2022-09-01)